Gene therapy might provide a useful treatment for a number of neurological diseases and a great deal of effort is going into the development of vector systems which will allow the delivery of potentially therapeutic genes to terminally differentiated neurons within the intact mammalian brain. The ability of herpes simplex virus type 1 (HSV-1) to establish a lifelong latent infection within neurons has led to interest in its use as a neuronal gene delivery vector. During HSV latency no viral proteins are produced and transcription from the latent viral genome is limited to a family of nuclear RNAs, the latency-associated transcripts, whose function is not well understood. Obtaining prolonged expression of a transgene in latently infected neurons has proven difficult due to transcriptional silencing of exogenous promoters introduced into the latent viral genome. For this reason there is a great deal of interest in utilizing the HSV latencyassociated promoter to drive the expression of therapeutic genes in latently infected neurons of both the peripheral and central nervous systems. In this review we describe a strategy which allows the latency-associated promoter to drive long-term reporter gene expression in the mammalian nervous system. These observations open up the possibility of using similar HSVbased vectors to express therapeutic transgenes within the brain and investigate the potential of gene therapy in a range of neurological disorders.
INTRODUCTION
Gene therapy has potential applications in the treatment of many diseases, including inborn errors of metabolism, infectious diseases and cancer. Each application will involve a different strategy, be it stable, long-term gene host cell, should make ideal gene delivery vectors, and much effort has gone into the development of viral vector systems [1] .
It has been suggested that gene therapy may be used to treat neurological disorders, including tumours, neurodegenerative diseases and metabolic defects [2] . Most of these applications require the development of gene delivery vectors that are able to transduce fully differentiated neurons in vivo and mediate long-term, stable expression of the therapeutic transgene. To this end a number of viral vector systems are being developed for neuronal gene delivery. Disabled adenoviral vectors can mediate reporter gene expression in many central nervous system (CNS) cell types, including neurons [3, 4] . Whether adenoviral vectors are capable of persisting for long periods in the absence of viral replication is questionable, however, and it seems that transgene expression from truly replication-defective adenoviral vectors is limited to about 6 weeks in neurons [5] . Adenoassociated virus (AAV) is a very attractive candidate as a somatic cell gene delivery vector and has been used for neuronal gene delivery [6, 7] . However, the difficulty of propagating high-titre stocks of recombinant AAV and its small coding capacity have restricted the utility of presently available AAV-based vectors. The combination of the AAV inverted terminal repeats and Rep protein to allow efficient, site-specific integration of plasmid sequences into chromosome 19 is very attractive to those developing gene delivery vectors. There is much interest in the possibility of using this machinery with other vectors such as the herpes simplex virus (HSV) amplicon to make hybrid gene delivery systems [8] . Retroviral vectors are the best characterized viral gene delivery system but the prototypic amphotropic murine retrovirus-based vectors can only transduce actively dividing cells and are thus of little use for gene delivery to quiescent somatic cells, such as neurons, in vivo. Lentiviruses, however, are not subject to these constraints, and an HIV-based vector system has recently been developed for neuronal gene delivery [9] and seems to be highly efficient [5] . Despite inevitable safety concerns, on the basis of these preliminary studies, lentiviral vectors appear to present a very promising tool for somatic cell gene delivery.
Herpes simplex virus type 1 (HSV-1) is a natural pathogen of man, being the causative agent of recurrent oro-labial cold sores. As well as undergoing acute, lytic replication in a wide range of cell types, the virus establishes a lifelong latent infection in neurons [10] . This property of the virus has led to much interest in the development of HSV-1 as a neuronal gene delivery vector [11, 12] . In this article we review recent work from our laboratory which has been directed at constructing HSV-based vectors capable of mediating indefinite transgene expression within latently infected neurons.
HSV LATENCY
A common biological feature of herpes viruses is their ability to maintain lifelong infection of the host despite an ongoing immune response. Periodic re-activation and shedding of infectious virus then allows the infection of new hosts and maintains high levels of viral infection, and seropositivity, within the population.
Historically, the link between surgical procedures on the trigeminal ganglion and the appearance of herpetic lesions, first described by Cushing [13] , and observations by Goodpasture that cold sores in man recurred at the same anatomical site but that no virus could be cultured from the skin between attacks [14] , led to the suggestion that HSV established a latent infection within sensory neurons. More recently, studies on human tissue have confirmed that viral DNA is present within the trigeminal ganglia of cadavers which exhibit no evidence of active disease [15] . Further characterization of this latent infection in humans has been limited, but it has been demonstrated that although no viral antigen can be detected in, and no virus isolated from, freshly dissected sensory ganglia, infectious virus is produced in these tissues after culture for a few days [16] [17] [18] [19] . This reservoir of viral DNA thus appears to be a potential source for viral re-activation and recurrent clinical lesions.
Further investigation of HSV latency has required the Mice are infected by subcutaneous injection of virus into the pinna of the ear. Virus replicates in the skin and a lesion is formed. Progeny virus is able to gain access to the terminals of sensory neurons innervating the site of inoculation, and virus is transported retrogradely up the axon to the neuronal cell body in the dorsal root ganglion. Within the dorsal root ganglion lytic cycle replication is rapidly controlled and the virus is able to establish a latent infection in sensory neurons. Neuronal gene delivery using herpes simplex virus development of animal models of infection. Although man is the only natural host of HSV infection, experimental infection of a number of animal species is possible and much work has been done using small rodent and lagomorph models of HSV latency. The research described here has utilized the mouse ear model [20] . Infection of the ear pinna leads to productive replication within epithelial cells, and the formation of a lesion which resembles a cold sore. Virus particles released into the dermis are able to enter the terminals of sensory axons and are transported retrogradely up the axon to the neuronal cell bodies in the relevant sensory ganglia ( Figure 1 ). Only limited replication occurs in the ganglia, followed by the establishment of a latent infection. HSV establishes a true latent infection, and no viral protein synthesis has been detected in latently infected neurons. A family of nuclear RNA species, the latencyassociated transcripts (LATs) are, however, transcribed in at least some latently infected neurons (see Figure 3b ). These transcripts derive from a single transcription unit located in the repeat sequences flanking the unique long (U L ) region of the viral genome ( Figure 2) . As yet the function of the LATs is not clearly defined, but they may have roles to play in both the establishment of latency and in reactivation [10] .
DEVELOPMENT OF HSV-BASED VECTORS
In addition to its ability to establish lifelong neuronal latency, other factors make HSV an attractive candidate as a gene delivery vector. The virus is relatively stable and purified stocks of virus containing 10"! p.f.u.\ml can routinely be prepared. The large genome contains numerous non-essential genes which can be deleted to allow many kilobases of foreign DNA sequences to be inserted, allowing the delivery of intact genes with complex regulatory elements rather than cDNAs under the control of simple promoters. The episomal nature of the latent genome [21] also means that the possible problems of disruption or activation of cellular genes, which could occur with vectors that integrate into the genome (i.e. retrovirus and AAV vectors), are avoided.
There are also potential problems associated with the use of HSV vectors. The wild-type virus is highly cytotoxic and injection of small amounts of virus into the brains of animals rapidly induces fatal encephalitis ; the development of replication-defective viruses is of paramount importance. The high prevalence of seropositivity to HSV-1 (approximately. 80 %) in the general population might present an obstacle to efficient viral delivery, although direct injection into the CNS may circumvent this [22] . This high frequency of previous exposure to HSV also raises the possibility of recombination\re-activation events between the vector genome and latent wild-type viral genomes already present in the host. All these issues will need to be addressed before HSV-based vectors could be considered for clinical application.
At present the development of HSV vectors is at an early stage and two fundamental problems need to be addressed. First, non-cytotoxic HSV vectors which are ' safe ' for the individual and for the population as a whole are required. Second, strategies for obtaining prolonged, stable transgene expression from the latent viral genome need to be developed.
The cascade nature of HSV gene expression means that by blocking immediate early (IE) gene expression it is possible to prevent expression of all other viral genes. Only two of the five IE gene products are essential for viral propagation in tissue culture and these can be provided in trans by a complementing cell line. By sequential deletion of the IE genes, and construction of suitable complementing cell lines, considerable progress has been made towards producing an HSV vector which is entirely non-cytotoxic when used to infect noncomplementing cells [23, 24] . Such vectors are still able to efficiently establish latency in vivo [25, 26] and should provide a suitable backbone for a neuronal gene delivery vector. These issues of vector safety are important and we have addressed them in more detail in a previous review [12] . In this review, we will concentrate on what is required to obtain long-term transgene expression within the latently infected neuron.
STRATEGIES FOR OBTAINING TRANSGENE EXPRESSION FROM THE LATENT HSV GENOME
The second problem that needs to be addressed in developing HSV for neuronal gene delivery is that of latent-phase transgene expression. As already discussed, the LATs are the only RNA species transcribed from the latent viral genome. All viral lytic cycle promoters are effectively silenced during latency and it has not been possible to demonstrate long-term gene expression using vectors in which reporter gene expression is driven by lytic cycle promoters [25, [27] [28] [29] . This transcriptional silencing also extends to most heterologous promoters inserted into the viral genome. When experimental animals are infected with recombinant viruses containing strong promoter elements, such as the Moloney Murine Leukaemia Virus (MoMuLV) long terminal repeat and the human cytomegalovirus (HCMV) IE promoter, which drive expression of lacZ, abundant expression of β-galactosidase (βgal) can be observed during the acute phase of infection. However, once latency has been established, much lower levels of βgal expression have been observed in only a minority of the latently infected neurons [30, 31] (see Figures 5a and 5b) . It has been suggested that this transcriptional silencing of the latent genome may be due to nucleosomal repression [32] . In the context of an HSV amplicon (a vector system which uses HSV as a helper virus to package plasmids containing an HSV origin of replication and packaging signal as well as a promoter-reporter gene construct [33] ), it has been possible to obtain prolonged transgene expression using neuronal-specific promoter elements of many kilobases in length, such as the tyrosine hydroxylase promoter [34, 35] , and similar constructs may also prove useful in the context of the viral genome.
An alternative approach has been to try to harness the virus's endogenous latency-associated promoter (LAP) to drive expression of a reporter gene during latency rather than expression of the LATs. This has also proved to be difficult. It has not been possible to define an LAP fragment that can be used to drive latent-phase gene expression when inserted into an exogenous locus in the viral genome [31] . If a transgene is inserted immediately downstream of the LAP transcriptional start site in its native locus (Figure 2c) , it is possible to obtain acutephase expression of the transgene, but there is little expression in latently infected neurons [36, 37] . Thus it seems that there are important elements in the sequences downstream of the transcription start site which need to be maintained if the promoter is to function during latency.
There is, however, some evidence that elements within the LAT transcription unit may be able to confer longterm activity on other promoter elements if they are inserted into the viral terminal repeats [38, 39] . It has also been shown that a hybrid promoter containing MoMuLV long terminal repeat and LAP-derived sequences can drive long-term transgene expression [31] . Our initial attempts at obtaining latent-phase gene expression therefore focused on the insertion of promoter-reporter gene cassettes into the LAT region.
INSERTION OF PROMOTERñREPORTER GENE CASSETTES INTO THE LAT LOCUS
To characterize the ability of heterologous promoter elements to drive latent-phase gene expression when inserted into the LAT region, we made a series of recombinant viruses containing promoter-reporter gene cassettes inserted into the major LAT gene about 1.5 kb downstream of the LAT transcription start site [40, 41] (Figure 3a) . In these constructs, two different promoter elements were utilized : the HCMV IE promoter, a strong viral RNA polymerase type II promoter, and a murine RNA polymerase type I promoter (RNA polymerase type I is responsible for transcription of the ribosomal Neuronal gene delivery using herpes simplex virus RNAs and is constitutively active in all cell types, including neurons [42] ). With viruses containing either of these promoters inserted into the LAT locus, abundant reporter gene expression could be detected during lytic infection of cells in tissue culture, or within murine dorsal root ganglia (DRG) at acute times post infection (Figure 5a) . It was not possible, however, to demonstrate continuing promoter activity in latently infected neurons (Figure 5b) , and it did not seem that the adjacent LAP was able to confer latent-phase activity on these heterologous promoters.
In an attempt to confirm that these recombinant viruses were capable of establishing latency we performed an in situ hybridization analysis of sections of latently infected ganglia using a riboprobe specific for the viral LATs. Since the major LAT locus had been disrupted by the insertion of the promoter-reporter gene cassette in these viruses, it was not possible to detect accumulation of the major LAT intron within the nuclei of latently infected neurons. It was, however, possible to detect LAP-derived cytoplasmic transcripts within the latently infected neurons [40] (Figure 3b) . Thus, insertion of foreign sequences 1.5 kb downstream of the LAP resulted in the maintenance of elements necessary for long-term LAP activity. This LAP-driven transcription extends through the 5h 1.5 kb of the LAT gene and into the insertion cassette. If a reporter gene was to be inserted into this locus, in the same orientation as the LATs, it should be efficiently transcribed in latently infected neurons.
HARNESSING THE LAP FOR LONG-TERM TRANSGENE EXPRESSION
Insertion of a reporter gene 1.5 kb downstream of the LAT transcription start site results in the production of latent-phase transcripts which contain 1.5 kb of 5h leader upstream of the start codon of the reporter gene (Figures  3a and 3b) . Sequence analysis of HSV-1 strain 17 [43] shows that this leader sequence contains 10 AUG codons and it therefore seems very unlikely that a ribosome scanning from the 5h cap of the mRNA would reach the authentic initiation codon of the reporter gene. This problem can be circumvented by using an internal ribosomal entry site (IRES). IRESs are sequence elements found in the genomes of the picornaviruses which function to allow ribosomes to bind directly to the middle of mRNA in a 5h-end-independent, cap-independent manner [44] . By linking the reporter gene to an IRES, it should be possible to obtain efficient translation despite the presence of a long 5h leader sequence.
The recombinant virus SC16 LβA contains the lacZ gene linked to the encephalomyocarditis IRES, inserted into the LAT region [41] (Figure 4) . In neurons latently infected with this virus, transcription from the LAP produces mRNA that is efficiently translated by internal ribosomal entry at the IRES. When mice are infected with this virus, only low levels of βgal expression can be detected in DRG at acute time points (Figure 5c ), but once latency has been established, large numbers of βgal-expressing neurons can be detected (Figure 5d ) [41] . Time-course experiments indicate that, as with LAT expression from a wild-type virus, βgal continues to be expressed in latently infected neurons over many months [41] . We know that in neurons latently infected with wild-type virus the LATs are expressed for the lifetime of the animal. By extension this would imply that in neurons latently infected with SC16 LβA, the expression of transgene from the LAP should also be lifelong.
ACTIVITY OF THE LAP WITHIN THE CNS
By inserting an IRES-linked transgene 1.5 kb downstream of the LAP, indefinite transgene expression within latently infected sensory neurons of the peripheral nervous system has been obtained [41] . For most potential therapeutic uses, however, it will be necessary to obtain long-term gene expression in many neuronal types within the brain. Does the LAP remain active when other types of neuron are latently infected with HSV ?
Latent HSV DNA can be detected within the brainstems of mice which have been infected with a wild-type virus via the ear or corneal routes [15, [45] [46] [47] . Using in situ hybridization it has been possible to demonstrate expression of LATs in motor neurons of the hypoglossal nucleus after infection of the tongue [38] and throughout the trigeminal system after corneal inoculation of virus [48] . LAT expression has also been detected by in situ hybridization in human brainstems [49] . In mice surviving intranasal inoculation of wild-type virus, LATs were detected in 70 % of the trigeminal ganglia, and also in 50 % of brainstems and 20 % of the cerebral and cerebellar hemispheres, using a reverse transcriptase\ polymerase chain reaction-based method [50] . It therefore appears that wild-type virus is able to establish transcriptionally active latency in a number of different regions of the brain, although the efficiency of latency establishment, and\or the transcription of LATs, may be less than in the peripheral sensory ganglia.
After infection of mice by the ear route, virus has been shown to gain access to the brainstem via the facial nerve, which supplies motor fibres to the muscles of the ear [51] . When brainstems from mice latently infected with SC16 LβA were histochemically stained for βgal activity, it was possible to demonstrate βgal-expressing neurons within the facial nerve nucleus (Figure 5e ), and also in the hypoglossal nerve nucleus and the spinal cord [41] . It thus appears that the LAP is able to mediate transgene expression in a variety of different cell types within the CNS as well as within the peripheral nervous system.
A SUITABLE VECTOR FOR GENE DELIVERY TO THE BRAIN
Vectors which are to be used for gene delivery to the brain will need to be replication defective and will probably require administration by stereotactic injection. Neuronal gene delivery using herpes simplex virus The genomes of replication-defective viruses have been shown to be capable of persisting within the brain in a number of different regions (e.g. hippocampus and nigrostriatal pathway) [28, 32, 52, 53] . It is unclear how the latency established by these replication-defective viruses relates to the latent infection established by wild-type viruses. When replication-defective viruses are used to establish latency in peripheral sensory neurons, LAT expression is easily detected [26] . Is there evidence that the LAP will be active within CNS neurons latently infected with such disabled vectors ? LAT expression has been demonstrated after stereotactic injection of a replication-defective virus into various regions of the rat brain [54] . Other studies have shown that, after stereotactic injection of a ribonucleotide reductase-deficient virus into rat hippocampus, the levels of both viral genomic DNA and LATs were stable from 1 to 8 weeks post injection [52] . There were about 15 LAT molecules per genome equivalent in hippocampal sections, which compared with the detection of 50 LAT molecules per genome when similar analyses were carried out on trigeminal ganglia latently infected with the same virus [55] . These data provide encouraging evidence that, in the context of a defective viral vector, levels of LAP transcription within latently infected hippocampal neurons are similar to those within neurons of DRG.
Current efforts are aimed at the construction of replication-defective viruses which will express βgal from the LAP during latency. Using such vectors it should be possible to investigate the range of cells in which transcriptionally active latency can be established and the levels of transgene expression which can be obtained, and to determine the degree of vector-associated cytotoxicity and inflammation. In addition, vectors which can be used to express potential therapeutic genes are being constructed in order to assess their ability to correct CNS metabolic disease in suitable mouse models (e.g. TaySachs disease [56] or Niemann-Pick Disease type C [57] ) and thereby prove the therapeutic utility of gene delivery. These are important early steps towards the development of HSV-based vectors for clinical use.
